This is a brief review of pancreaticobiliary maljunction. The basic treatment for this condition includes either cholecystectomy or extrahepatic bile duct resection. When the condition is accompanied by malignancies, a radical operation should be the first treatment option. Knowledge on molecular pathogenesis is gradually increasing. However, studies should be expanded to include larger patient cohorts, and other types of molecules should be carefully investigated and analyzed.

Kazumi I, Kodama T: A case report and the etiology of cystic dilatation (in Japanese). Tokyo Med Assoc 1916;30:1413–1423.
Babbitt DP: Congenital choledochal cysts: new etiological concept based on anomalous relationships of the common bile duct and pancreatic duct. Ann Radiol (Paris) 1969;12:231–241.
Komi N, Kuwashima T, Kuramoto M, et al: Anomalous arrangement of the pancreaticobiliary ductal system in choledochal cyst. Tokushima J Exp Med 1976;23:37–48.
The Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM): The Committee of JSPBM for Diagnostic Criteria – Diagnostic criteria of pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 1994;1:219–221.
Kimura Y, Hirata K: Pathological findings and carcinogenesis: histopathological characteristics of biliary tract carcinomas arising from the pancreaticobiliary maljunction; in Koyanagi Y, Aoki T (eds): Pancreticobiliary Maljunction. Tokyo, Igakutosho Shuppan, 2002, pp 253–260.
Kimura K, Ohto M, Saisho H, et al: Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258–1265.
Kimura K, Iwan N: Pancreatico-biliary maljunction with respect to gallbladder carcinoma. Dig Semin 1987;27:153–160.
Chao TC, Wang CS, Jan YY, et al: Carcinogenesis in the biliary system associated with APDJ. J Hepatobiliary Pancreat Surg 1999;6:218–222.
Tashiro S, Imaizumi T, Ohkawa H, et al: Nationwide Survey: overall report on the registration study of the Japanese Study Group on Pancreaticobiliary Maljunction for the past 10 years; in Koyanagi Y, Aoki T (eds): Pancreaticobiliary Maljunction. Tokyo, Igakutosho Shuppan, 2002, pp 401–410.
Watanabe Y, Toki A, Todani T: Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg 1999;6:207–212.
Isozaki H, Okajima K, Hara H, et al: Proliferating cell nuclear antigen expression in the gallbladder with pancreaticobiliary maljunction. J Surg Oncol 1997;65:46–49.
Witzba II, Gazdar AF, Roa I, et al: p53 protein overexpression in gallbladder carcinoma and its precursor lesion. An immunohistochemical study. Hum Pathol 1996;27:360–365.
Wee A, Teh M, Raju GC, et al: Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J Clin Pathol 1994;47:453–456.
Roa I, Villaseca M, Araya J, et al: p53 tumor suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997;31:226–230.
Hanada K, Itoh M, Fujii K, et al: K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of pancreaticobiliary ducts. Cancer 1996;77:452–458.
Aoki T, Tsuchida A, Kasuya K, et al: Carcinogenesis in pancreaticobiliary maljunction; in Koyanagi Y, Aoki T (ed): Pancreaticobiliary Maljunction. Tokyo, Igakutosho Shuppan, 2002, pp 295–302.
Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC compete for the interactions with β-catenin and cytoskelton. J Cell Biol 1994;127:2061–2069.
Gumbiner BM: Signal transduction by β-catenin. Curr Opin Cell Biol 1995;7:634–640.
Kimura Y, Furuhata T, Mukaiya M, et al: Frequent β-catenin alteration in gallbladder carcinomas. J Exp Clin Cancer Res 2003;22:321–328.
Hui AM, Li X, Shi YZ, et al: Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res 2000;6:4272–4277.
Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422–426.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.